REV1 Inhibition Enhances Radioresistance and Autophagy
Cancer therapy resistance is a persistent clinical challenge. Recently, inhibition of the mutagenic translesion synthesis (TLS) protein REV1 was shown to enhance tumor cell response to chemotherapy by triggering senescence hallmarks. These observations suggest REV1's important role in determining cancer cell response to chemotherapy. Whether REV1 inhibition would similarly sensitize cancer cells to radiation treatment is unknown. This study reports a lack of radiosensitization in response to REV1 inhibition by small molecule inhibitors in ionizing radiation-exposed cancer cells. Instead, REV1 inhibition unexpectedly triggers autophagy, which is a known biomarker of radioresistance. We report a possible role of the REV1 TLS protein in determining cancer treatment outcomes depending upon the type of DNA damage inflicted. Furthermore, we discover that REV1 inhibition directly triggers autophagy, an uncharacterized REV1 phenotype, with a significant bearing on cancer treatment regimens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Cancers - 13(2021), 21 vom: 21. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ikeh, Kanayo E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autophagy |
|---|
| Anmerkungen: |
Date Revised 06.04.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers13215290 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333092759 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333092759 | ||
| 003 | DE-627 | ||
| 005 | 20231225220928.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers13215290 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1110.xml |
| 035 | |a (DE-627)NLM333092759 | ||
| 035 | |a (NLM)34771454 | ||
| 035 | |a (PII)5290 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ikeh, Kanayo E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a REV1 Inhibition Enhances Radioresistance and Autophagy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 06.04.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Cancer therapy resistance is a persistent clinical challenge. Recently, inhibition of the mutagenic translesion synthesis (TLS) protein REV1 was shown to enhance tumor cell response to chemotherapy by triggering senescence hallmarks. These observations suggest REV1's important role in determining cancer cell response to chemotherapy. Whether REV1 inhibition would similarly sensitize cancer cells to radiation treatment is unknown. This study reports a lack of radiosensitization in response to REV1 inhibition by small molecule inhibitors in ionizing radiation-exposed cancer cells. Instead, REV1 inhibition unexpectedly triggers autophagy, which is a known biomarker of radioresistance. We report a possible role of the REV1 TLS protein in determining cancer treatment outcomes depending upon the type of DNA damage inflicted. Furthermore, we discover that REV1 inhibition directly triggers autophagy, an uncharacterized REV1 phenotype, with a significant bearing on cancer treatment regimens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a REV1 | |
| 650 | 4 | |a autophagy | |
| 650 | 4 | |a etoposide | |
| 650 | 4 | |a ionizing radiations | |
| 650 | 4 | |a radioresistance | |
| 650 | 4 | |a translesion synthesis | |
| 700 | 1 | |a Lamkin, Erica N |e verfasserin |4 aut | |
| 700 | 1 | |a Crompton, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Deutsch, Jamie |e verfasserin |4 aut | |
| 700 | 1 | |a Fisher, Kira J |e verfasserin |4 aut | |
| 700 | 1 | |a Gray, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Argyle, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Won Y |e verfasserin |4 aut | |
| 700 | 1 | |a Korzhnev, Dmitry M |e verfasserin |4 aut | |
| 700 | 1 | |a Hadden, M Kyle |e verfasserin |4 aut | |
| 700 | 1 | |a Hong, Jiyong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Pei |e verfasserin |4 aut | |
| 700 | 1 | |a Chatterjee, Nimrat |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 13(2021), 21 vom: 21. Okt. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:21 |g day:21 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers13215290 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 21 |b 21 |c 10 | ||